<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000973</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 102</org_study_id>
    <secondary_id>11077</secondary_id>
    <nct_id>NCT00000973</nct_id>
  </id_info>
  <brief_title>A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients</brief_title>
  <official_title>Pyrimethamine Pharmacokinetics in HIV Positive Patients Seropositive for Toxoplasma Gondii</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glaxo Wellcome</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the manner in which pyrimethamine is metabolized and excreted in patients&#xD;
      currently receiving zidovudine (AZT). An important goal of this measurement is to establish&#xD;
      the optimal dose of pyrimethamine necessary to prevent the development of toxoplasmosis in&#xD;
      AIDS patients or delay the subsequent return of toxoplasmic encephalitis.&#xD;
&#xD;
      Encephalitis caused by Toxoplasma gondii has emerged as the most frequent cause of focal&#xD;
      central nervous system infection in patients with AIDS. Untreated, the encephalitis is fatal.&#xD;
      The best treatment for this disease has not been determined. Presently it is standard&#xD;
      practice to administer a combination of pyrimethamine and sulfadiazine. Little is known about&#xD;
      the pharmacokinetics of pyrimethamine in patients with AIDS receiving AZT. Furthermore, there&#xD;
      are reports that patients already exposed to toxoplasmosis may not have uniform absorption of&#xD;
      pyrimethamine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Encephalitis caused by Toxoplasma gondii has emerged as the most frequent cause of focal&#xD;
      central nervous system infection in patients with AIDS. Untreated, the encephalitis is fatal.&#xD;
      The best treatment for this disease has not been determined. Presently it is standard&#xD;
      practice to administer a combination of pyrimethamine and sulfadiazine. Little is known about&#xD;
      the pharmacokinetics of pyrimethamine in patients with AIDS receiving AZT. Furthermore, there&#xD;
      are reports that patients already exposed to toxoplasmosis may not have uniform absorption of&#xD;
      pyrimethamine.&#xD;
&#xD;
      Patients receive the study treatment for a total of 22 days. Patients are given an initial&#xD;
      dose of pyrimethamine followed by a lower dose given as a single oral daily dose for 21 days.&#xD;
      Patients continue to receive AZT at the dose prescribed prior to enrollment in the study.&#xD;
      Patients receive leucovorin calcium once a day. Neither the leucovorin calcium nor the AZT&#xD;
      are provided through the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">March 1995</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>26</enrollment>
  <condition>Toxoplasmosis, Cerebral</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrimethamine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Aerosolized pentamidine for Pneumocystis carinii pneumonia prophylaxis.&#xD;
&#xD;
          -  Isoniazid not initiated during study period.&#xD;
&#xD;
          -  Methadone maintenance.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Stable prescribed dose of zidovudine (AZT) of at least 500 mg/day.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Prior history of toxoplasmic encephalitis.&#xD;
&#xD;
          -  Unable to take oral medication reliably or have a malabsorption syndrome (i.e., 3 or&#xD;
             more loose stools/day for at least 4 weeks associated with an unintentional weight&#xD;
             loss of = or &gt; 10 percent of body weight).&#xD;
&#xD;
          -  History of sensitivity to the study medications.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Maintenance therapy for opportunistic infections with macrolides or sulfonamides,&#xD;
             immunomodulators, rifampin, amphotericin, dapsone, ganciclovir, antifolates,&#xD;
             probenecid, benzodiazepines, nephrotoxins, and experimental cytotoxic chemotherapy.&#xD;
&#xD;
          -  Medications such as aspirin, benzodiazepines, cimetidine, indomethacin, morphine, and&#xD;
             sulfonamides should be avoided.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Lymphocyte replacement.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Any medical or social condition that, in the opinion of the investigator, would&#xD;
             adversely affect either participation or compliance in the study.&#xD;
&#xD;
          -  Diagnosis of AIDS and febrile and have evidence of another serious opportunistic&#xD;
             infection or central nervous system impairment.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Maintenance therapy for opportunistic infections with macrolides or sulfonamides,&#xD;
             immunomodulators, rifampin, amphotericin, dapsone, ganciclovir, antifolates,&#xD;
             probenecid, benzodiazepines, nephrotoxins, and experimental cytotoxic chemotherapy&#xD;
             within past 14 days.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Lymphocyte replacement within past 14 days.&#xD;
&#xD;
        Patients have the following symptoms and conditions:&#xD;
&#xD;
          -  Laboratory evidence of HIV infection.&#xD;
&#xD;
          -  Serological evidence of exposure to Toxoplasma gondii, but no clinical evidence of&#xD;
             active toxoplasmic infection.&#xD;
&#xD;
          -  Able to understand and sign a written informed consent.&#xD;
&#xD;
          -  Either homosexual male or intravenous drug user.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  Stable prescribed dose of zidovudine (AZT) of at least 500 mg/day for 4 weeks.&#xD;
&#xD;
        Intravenous drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>B Luft</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Ctr.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jacobson JM, Davidian M, Rainey PM, Hafner R, Raasch RH, Luft BJ. Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii. Antimicrob Agents Chemother. 1996 Jun;40(6):1360-5. doi: 10.1128/AAC.40.6.1360.</citation>
    <PMID>8726001</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Toxoplasmosis</keyword>
  <keyword>Toxoplasma</keyword>
  <keyword>Pyrimethamine</keyword>
  <keyword>Leucovorin</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Encephalitis</keyword>
  <keyword>Zidovudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Toxoplasmosis</mesh_term>
    <mesh_term>Toxoplasmosis, Cerebral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

